Uncategorized

Douglas Devine will stay on as a consultant through 2024, as the company goes through a restructuring to become “a larger digital healthcare organization.” 

Some states are proposing to unwind Medicaid coverage more slowly, while others are moving more quickly to focus on reducing budgetary costs, according to a survey from the Kaiser Family Foundation.

If Tandem can prove to regulators that the system can help manage young children’s diabetes, it could compete with Medtronic and Insulet, which have devices that are indicated for use in kids as young as two years.

Q4 and full-year 2022 financial statements have revealed several companies slashing I-O pipelines. Here are just some of the factors at play.

Job hopping– frequently changing jobs, typically within a short period of time – gained popularity with the onset of COVID-19 and is still popular now. Here’s what recruiters think about job hopping.

Updating base physician payment rates by 1.45% in 2024 as proposed by the group that advises Congress on Medicare policy is “grossly insufficient,” the Medical Group Management Association said in a statement.

The new financing will help the Boston-based biotech accelerate the development of its siRNA-based therapies for immuno-dermatology indications.

Seamless Therapeutics launched Wednesday with $12.5 million in seed financing to develop its programmable recombinases for gene editing.

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced financial results for the fourth quarter ended December 31, 2022 and provided an update on clinical and corporate developments.

Invitae today announced the appointment of W. Michael Korn, M.D., as its chief medical officer for oncology, effective March 13, 2023.